Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 1
A Phase I, First in Human (FIH), Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with …
Lung Cancer (NSCLC)Prostate CancerEsophageal Cancer+1 more
Estimated
~$10 – $8,750
Phrontline BiopharmaNCT07181473
Phase 1
PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed …
Participants With Advanced Solid Tumor Malignancies
Estimated
~$10 – $8,750
VelaVigo Bio IncNCT07136779
Phase 1
A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. Th…
Solid Tumor MalignanciesColorectal CarcinomaSmall Cell Lung Cancer ( SCLC )+4 more
Estimated
~$10 – $8,750
Tasca TherapeuticsNCT07030257
Phase 1
A Phase 1, Open-label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB168 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Malignancies
The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The …
Solid Tumor Malignancies
Estimated
~$10 – $8,750
Kumquat Biosciences Inc.NCT06994806